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CardiomyopathyAMP-activated protein kinase (AMPK), the key sensor and regulator of cellular energy status, is a hetero-
trimeric enzyme with multiple isoforms for each subunit (α1/α 2; β1/β2; γ1/γ2/γ3). Mutations in
PRKAG2, which encodes the γ2 regulatory subunit, cause a cardiomyopathy characterized by hypertrophy
and conduction abnormalities. The two reported PRKAG2 transcript variants, γ2-short and γ2-long (encoding
328 and 569 amino acids respectively), are both widely expressed in adult tissues. We show that both γ2
variants are also expressed during cardiogenesis in mouse embryos; expression of the γ3 isoform was also
detected unexpectedly at this stage. As neither γ2 transcript is cardiac speciﬁc nor differentially expressed
during embryogenesis, it is paradoxical that the disease is largely restricted to the heart. However, a recently
annotated γ2 transcript, termed γ2-3B as transcription starts at an alternative exon 3b, has been identiﬁed; it
is spliced in-frame to exon 4 thus generating a protein of 443 residues in mouse with the ﬁrst 32 residues
being unique. It is increasingly expressed in the developing mouse heart and quantitative PCR analysis
established that γ2-3B is the major PRKAG2 transcript (~60%) in human heart. Antibody against the novel N-
terminal sequence showed that γ2-3B is predominantly expressed in the heart where it is the most abundant
γ2 protein. The abundance of γ2-3B and its tissue speciﬁcity indicate that γ2-3B may have non-redundant
role in the heart and hence mediate the predominantly cardiac phenotype caused by PRKAG2mutations.
© 2012 Elsevier Ltd. Open access under CC BY-NC-ND license. 1. Introduction
AMP-activated protein kinase (AMPK) is an evolutionarily con-
served sensor of nutritional and environmental stress. The hetero-
trimeric complex is composed of the catalytic α, the scaffolding β and
the nucleotide binding γ subunits. There are two or three isoforms of
each subunit in mammals (α1 and α2; β1 and β2; γ1, γ2 and γ3),
each encoded by different genes [1,2]. Theα1 and β1 subunits are ubiq-
uitously expressedwhereasα2 and β2 expression is relatively higher in
cardiac and skeletal muscle than in other tissues [3]. Of the γ isoforms,
γ1 and γ2 are expressed quite uniformly throughout different tissues
whereas γ3 has only been detected in skeletal muscle [2]. The γ1
isoform is the major regulatory subunit, being present in complexes
that account for 80–90% of total AMPK activity in all tissues [2]. In endo-
thelial cells, AMPK containing the γ2 subunit has been localized to the
cytokinetic apparatus where it may regulate mitotic processes [4].
Two major AMPK γ2 variants have been reported, produced by
transcription from different promoters: γ2-short (also termed γ2b), a+44 1865 234667.
d).
Loo Lin School of Medicine,
-NC-ND license. protein of 328 amino acids containing the four cystathione β-synthase
(CBS) domains responsible for adenine nucleotide binding, and γ2-
long (γ2a), which is composed of the γ2-short sequence plus a 241 res-
idue N-terminal extension [2,5].
Mutations in the PRKAG2 gene have been shown to cause a cardiac
speciﬁc phenotype of hypertrophywith associated glycogen deposition,
Wolff-Parkinson-White syndrome (WPW) and conduction abnormali-
ties [6–9]. All the reported mutations are located in the nucleotide-
binding domains and our present understanding is that the AMP bind-
ing is lower or abolished in the mutant protein and in consequence,
AMPK activation is impaired [10,11] but also that the basal activity is in-
creased [12]. The largely cardiac-restricted nature of the disease sug-
gests that AMPK γ2-containing complexes have a speciﬁc role,
different subcellular localization and/or particular temporal expression
in the heart. Certain PRKAG2mutations cause death at the fetal or neo-
natal stage and therefore γ2-AMPK must be present in the developing
heart where the relative expression of the γ isoforms has not been pre-
viously reported [13].
In order to understand the development of the cardiac disease with
γ2 mutations we studied the embryonic expression of the γ regulatory
subunits, γ1, γ3 and the two transcript variants of γ2 in mouse embry-
os. In the developing heart we detected a third, largely cardiac speciﬁc
γ2 transcript variant that becomes, with γ2-short, the major γ2 protein
in adult heart.
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2.1. Animals, tissue collection
All experiments were conducted in accordance with the UK Home
Ofﬁce Animals (Scientiﬁc Procedures) Act of 1986 and the Guide for
the Care andUse of Laboratory animals published by theUS National In-
stitutes of Health (NIH Publication No. 85-23, revised 1996). CD1 mice
were sacriﬁced, and embryos were collected at different embryonic
time points for immunohistochemistry studies and for RNA extraction
from isolated hearts. Hearts were also obtained from new-born and
adult CD1 mice. Organ samples for protein extraction were taken from
a 10 week-old male C57BL/6 mouse.
2.2. In situ hybridization
Riboprobes were ampliﬁed by PCR from mouse heart cDNA, using
transcript speciﬁc primers. The PCR fragments were cloned into
pGEM-T Easy. Sense and anti-sense riboprobes were labelled with
DIG-11-dUTP using the DIG RNA labeling kit (Roche). The primers for
the γ2-long probes were: GGACGAGGCACCGGAATTAAC (forward)–
GTATGTCGGGGATGCCAGCGGAGGTC (reverse); the probe is 698 bp.
The primers for the γ2-short probe were: CGCCCCCCGCCACTG
(forward)–GCCGCCAGCACCGCCTGAG; the probe is 107 bp and anneals
to a segment in the 5′ UTR.
In situ hybridization was performed in whole mount embryos,
using a published procedure [14].
2.3. Immuno-histochemistry
Mouse embryos were ﬁxed in 4% paraformaldehyde-phosphate
buffered saline (PFA-PBS), then dehydrated in increasing ethanol con-
centration, cleared in Histoclear, embedded in parafﬁn and 5–10 μm
sections were cut. Sections were rehydrated, and microwaved in a cit-
rate solution (Vector Laboratories) for antigen retrieval. We used Anti-
body Diluent (DAKO) for blocking before incubating the sections with
rabbit-anti-PRKAG2 (1:25); rabbit anti-PRKAG1 (1:50); rabbit anti-
PRKAG3 (1:50) for 1 h at room temperature. (All antibodies were pur-
chased from Zymed Laboratories.) Alkaline phosphatase conjugated
secondary antibodies (Vector laboratories) were applied for 1 h, and
staining was visualized using the Vector® Blue Alkaline Phosphatase
Substrate Kit III (Vector laboratories). Section was dehydrated and per-
manently mounted in Vectamount (Vector laboratories).
2.4. Real-time PCR
Semi-quantitative real-time PCR with QuantiTect SYBR Green RT-
PCR reagents (Qiagen) were carried out in triplicates using 20 ng RNA
isolated fromdeveloping and adultmouse hearts. Datawere normalized
against the housekeeping gene, metastatic lymph node 51 (MLN51),
that is expressedmore consistently during development than other, tra-
ditionally used housekeeping genes [15,16]. Primers for MLN51:
CGCCGAGGAGTCTGAGTGTG (forward) andTCGTTAGCTTCTGATTTCAGC
(reverse). Primers for γ2-short: CCCGATGCGAGAAGCCCG (forward)
and CTCTGCTTTTTACTTTCCCACAGCGGC (reverse); for γ2-long: ATCTA-
TGCTTCCTCGTCCCCTCCAG (forward) and AAAGCCACTTTCTGAGTCTTCTT
(reverse).
The primers to detectγ1: GCTGAGGAACTGGCGGGCG (forward) and
GGGAATTAGGTCATAGCAGC (reverse); to detect γ3: CTGTTCCCTT-
GGCTGAAGCGGAGACC (forward) and TGGGGCTGGGAACTCTATGGTCA
(reverse).
Relative expression of the γ2 transcript variants was quantiﬁed by
TaqMan® real-time PCRmethod using a human cDNApanel (Clontech).
Oligonucleotides, designed with the Primer Express 3.0 software are
listed in Supplement Table S1. Taqman MGB probes span exon-exon
or 5′ UTR-exon junctions. Beta-2 microglobulin was the endogenouscontrol. All primers and probes were custom made by Applied
Biosystems unless it is stated otherwise. Reactions were carried out
in StepOnePlus Real-Time PCR system using MicroAmp Fast Optical
96-well plates with Fast Master Mix, both purchased from Applied
Biosystems. Reactions (20 μl each) were set up in duplicates with 1 ng
cDNA, 200 nM probe and 900 nM primers. Expression was quantiﬁed
using the relative standard curve method (Applied Biosystems, user
bulletin #2).
2.5. Protein extraction and Western blot analysis
Organ samples were homogenized in 50 mM Tris–HCl, pH 7.5,
150 mM NaCl, 2% SDS, 1 mM PMSF and 1 mM dithiothreitol con-
taining complete protease inhibitor mix (Roche). Polyclonal antibody,
G2-3B was raised in rabbit against the KHL-conjugated peptide of
mouse γ2-3B (MKRFGSLRGTKKPKDQNRSTQRR-C) by Harlan UK
(Hillcrest). Rabbit polyclonal GAPDH antibody was obtained from
Abcam and rabbit polyclonal anti-PRKAG2 antibody was purchased
from Atlas-Antibodies.
2.6. Cell fractionation
The FractionPREP™ cell fractionation kit was purchased from Bio-
Vision and used according to manufacturer's instructions. Hearts
were obtained from C57BL/6 mice and processed immediately.
3. Results
3.1. Expression of PRKAG2 transcripts in adult mouse tissues
PRKAG2 is widely expressed throughout different tissues in human
and therefore the reason for the cardiac-restricted nature of the dis-
ease caused by PRKAG2 mutations is unclear [5]. In order to examine
whether either of the two major γ2 variants, γ2-short and γ2-long,
showed cardiac speciﬁc expression, we examined the expression of
PRKAG2 transcripts by real-time PCR in mouse heart, skeletal muscle,
liver, brain and kidney (Fig. 1). The primers were designed to distin-
guish between the transcripts: there is a unique 5′ untranslated
sequence (UTR) in the γ2-short transcript in front of exon 5 where
the forward primer anneals. While γ2-short expression is absent
from liver, it is present in the other tissues examined as is the tran-
script of γ2-long, and therefore neither γ2 variant is cardiac speciﬁc
in mouse.
3.2. Embryonic expression of the AMPK-γ subunits — in situ
hybridization
Differential expression of the PRKAG2 transcript variants may occur
during embryogenesis. Our ﬁrst choice to investigate this was in situ
hybridization since a riboprobe that hybridises to the 5′ UTR segment
of the γ2-short transcript can detect the γ2-short transcript separately
from γ2-long. However, early mouse embryos (8.5 dpc — day post
coitum) were similarly stained around the fusion of the neural fold,
folding ectoderm, somites, developing forebrain with both the γ2-
long and γ2-short riboprobes (Fig. 2) and at least at this stage, the
expression pattern of the two transcript variants appears to be very
similar.
The γ1 transcript, which is the major AMPK regulatory subunit in
adult, could not be detected in these embryos; even prolonged incu-
bation with the γ1-speciﬁc probe produced no colouration (not
shown). In contrast, hybridization with the γ3 riboprobe resulted in
strong, overall staining (not shown) that indicates an unexpected,
ubiquitous expression of γ3 at 8.5 dpc; γ3 expression has only been
shown in skeletal muscle in adults [2,17].
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Fig. 1. Transcription of γ2-short and γ2-long in mouse — real-time PCR. Relative ex-
pression of γ2-short and γ2-long in adult tissue samples; SYBR Green detection,
n=3. Cartoons of the DNA sequences show the unique 5′ UTR (black) of γ2-short,
the extended N-terminal region (white) of γ2-long and the nucleotide-binding region
(gray). The locations of the PCR products are indicated by solid lines.
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Since both γ2 transcripts and γ3 but not γ1 were detected in early
embryos, we switched to immunohistochemistry to investigate the
detailed expression pattern of all γ subunits in the developing embry-
onic tissues. Antibodies speciﬁc to each AMPK γ subunits are available
but only γ2-long can be detected separately with antibodies that rec-
ognize unique epitopes in the N-terminal extension of the γ2-long
protein. We sectioned and stained 10.5–12.5 dpc embryos with anFig. 2. Whole mound in situ hybridization of mouse embryos — 8–8.5 dpc. A: γ2-long,
B: γ2-short, dorsal view; sm — somite; ne — neural ectoderm; ↙ — sense probe as
control.N-terminal γ2 antibody and carried out experiments in parallel with
γ1 and γ3 antibodies (Fig. 3).
In mouse embryos, γ1 expression can be detected around 10.5 dpc
in distinct neural structures at ﬁrst instance, while γ2-long and γ3 ex-
pression continues. Strong γ2-long expression was detected in the
surface ectoderm and in the neurotube of 10.5 dpc embryos
(Fig. 3C). While γ1 becomes detectable at this stage it is not as widely
expressed as γ2 and γ3; the expression is mainly restricted to a few
structures showing overlapping staining with the γ3 antibody (10.5
dpc — e.g. sympathetic ganglion, Figs. 3A, E). There is some γ1
staining in the developing heart but it is still weak (Figs. 3A, B).
Staining of the sympathetic ganglion was conﬁrmed with the neural
speciﬁc NeuN antibody (not shown).
The staining pattern with the γ3 and the γ2-long antibodies
somewhat overlaps (ventricle — Figs. 3C, D, E, F) but there are differ-
ences: γ2-long is detected in the developing liver at 11.5 dpc while γ3
staining is not present there (Figs. 3D, F). The γ2 antibody also depicts
structures that are stained with the γ3 antibody as well (heart,
tongue, facial structures and kidney — not all are demonstrated inFig. 3. Immunohistochemistry—mouse embryos. Transverse (A, C, E) and sagittal (B, D,
F) serial sections were stained with γ1 — A–B; γ2 N-terminal — C–D; and γ3 — E–F an-
tibodies. Labeling: fba — ﬁrst branchial arch; int — intestine; lv — liver; mrl — marginal
layer neural tube;mtl—mantle layerneural tube; se— surface ectoderm; sg— sympathetic
ganglion; urg — urogenital ridge; v — ventricle.
345K. Pinter et al. / Journal of Molecular and Cellular Cardiology 53 (2012) 342–349Fig. 3), structures where abnormalities have been reported accompa-
nying the cardiac phenotype with certain γ2 mutations [13,18].3.4. Cardiac development in mouse embryos — immunohistochemistry
Focusing on the developing heart, here we show which speciﬁc
cardiac structures are stained with the different γ antibodies
(Fig. 4). The γ2-long antibody staining depicts the atria, common
ventricular chamber, epicardium and pericardium (Figs. 4D, C) and
γ2-long is also present in the atrio-ventricular junction that separates
the atria from the ventricle (Fig. 4C). The latter could be particularly
relevant as defects in this region are implicated in the development
of accessory pathways in patients with WPW. Strong γ3 staining
was detected in the developing heart: structures stained with the
γ2-long antibody are also stained with the γ3 antibody (Figs. 4E, F).
In addition, γ3 is also present in the outﬂow tract (Fig. 4E). In con-
trast, the γ1 staining, both in the atria and ventricles, was still weak
at 12.5 pc (Fig.4B); the strong staining of the vagus nerve overlapped
with γ3 staining and there was no γ2-long detected here (Figs. 4B, F).Fig. 4. AMPK γ proteins in developing mouse heart — immunohistochemistry. Sagittal
(A, D, E) and transverse (B, C, F) embryo sections stained with γ1, γ2 N-terminal (γ2)
and γ3 antibodies. Labelling: a — atria; avj — atrio-ventricular junction; cv — common
ventricular chamber; ep — epicardium; lv — left ventricle; oft — outﬂow tract; pc —
pericardium; rv — right ventricle; vg — vagus nerve.3.5. Expression of AMPK-γ subunits during cardiogenesis by real-time
PCR
In order to compare the expression of the γ subunits, real-time
PCR was performed on cDNA prepared from developing hearts from
13.5 dpc, this being the earliest time point when dissection of the
heart and extraction of sufﬁcient RNA was possible in our hands.
Each γ transcript, including γ1 was already clearly detectable at
13.5 dpc (Fig. 5). The expression of both γ2 transcripts, γ2-long tran-
scription especially, increased until birth after which the expression
levels of both, but in particular the short form, declined. Embryonic
expression of γ3 was unexpected as it had previously been reported
to be only present in adult skeletal muscle [2,17]. The γ3 expression
was unchanged from 13.5 dpc to birth when it sharply declined,
thus γ3 appears to function as an “embryonic” isoform in the heart.
The transcription of γ1 increased in the developing heart and
remained high, accounting for the reported predominance of γ1 in
the adult heart [2].1.4
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Fig. 5. Real-time PCR — γ transcripts in developing and adult heart. A: γ2-short and
-long; B: γ1 and γ3 transcription. SYBR Green detection; transcription level is
expressed as fractions of the values at birth in each case; the positions of the PCR products
from the γ2 transcripts as in Fig. 1; n=3.
AB
C
Fig. 7. The major γ2 transcript is γ2-3B in human heart — quantitative PCR. A: Human
cDNA panel — expression of γ2 or γ2-3B is shown as fraction of the γ2 transcription in
adult heart. B: Contribution of each γ2 transcript variant to the overall γ2 level in adult
human heart. C: The annealing sites of primers and probes.
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In an earlier report by Lang et al. [5], detection of PRKAG2 tran-
scripts in a human tissue panel by northern blot revealed the pres-
ence of an abundant band in the region of the short γ2 message
(2.4–3 kb), with the long transcript (3.8 kb) accounting for only a
small fraction of the total signal. Interestingly, the authors noted
that the band of the short transcript was actually a doublet, and the
slightly larger component (3 kb) was suggested to have a longer 3′
UTR. However, since that report two further PRKAG2 variants have
been identiﬁed and it is likely that the intermediate 3 kb transcript
represents one of these. One form, in which transcription starts in
exon 2 and encoding a protein of 525 amino acids, has been annotated
in human Ensembl; this has been referred to as γ2c in a recent report
[19]. However, we found very low levels of γ2c in human tissues
and in mouse its expression appeared to be restricted to the brain
(Supplement Fig. S2). Therefore we propose that the 3 kb γ2 transcript
is most likely to be the intermediate-sized γ2mRNA encoding a protein
of 443 (mouse) or 445 (human) residues recently annotated in both
mouse and human Ensembl databases (http://www.ensembl.org).
This mRNA is transcribed from another alternative promoter in the
PRKAG2 locus within intron 3 (Fig. 6). The transcript has a unique
starting exon (“3b”), which is spliced in-frame with exon 4, and the
rest of the sequence is therefore identical with that of γ2-long (see Sup-
plement Fig. S1). We refer to this new intermediate form as γ2-3B.
We ampliﬁed the entire coding sequence of γ2-3B by PCR using
cDNA from mouse and human heart (Supplement Fig. S3) and veri-
ﬁed the sequence in both cases. We applied a TaqMan-based real-
time PCR approach to quantify the contribution of γ2-3B transcript
to total γ2 mRNA in cDNA from a selection of human tissues
(Fig. 7). Both fetal and adult hearts contain substantially more γ2
than the other human tissues and approximately 50% of it is γ2-3B
(Fig. 7A). The level of γ2-3B in the heart is at least ﬁve times greater
than that found in skeletal muscle and brain, and over ten times
higher than the levels in other tissues. A similar pattern of expression
was found using semi-quantitative PCR analysis of mouse tissues
(Supplement Fig. S3).
Transcription of the total γ2, along with the γ2a, γ2b, γ2c and γ2-
3B variants was also quantiﬁed by TaqMan® real-time PCR method
using primers that anneal to the 5′ UTR of γ2-long and γ2-short with
probes annealing to the overlapping sequence of 5′ UTR and exon 1 in
each cDNA (Fig. 7C; sequences listed in Supplement Table S1). AnalysisSize:~ 300 kb
Fig. 6. Schematic representations of the PRKAGof adult human heart cDNA demonstrated that γ2-3B and γ2-short
transcripts are the major cardiac γ2 mRNAs (Fig. 7B, Supplement
Table S2). The γ2-long form appears to be a minor component (less
than 10% of total) and expression of γ2c was found to be negligible2 locus — transcription of the γ2 variants.
347K. Pinter et al. / Journal of Molecular and Cellular Cardiology 53 (2012) 342–349(Fig. 7B, Supplement Table S2). The γ3 mRNA level was also negligible
in heart but, as expected, high in skeletal muscle (Supplement Table
S2).
In order to conﬁrm the abundance of the γ2-3B variant at the
protein level we raised a rabbit polyclonal antibody against the unique
N-terminal peptide ofγ2-3B; this antibody (G2-3B) only recognizesγ2-
3B and its speciﬁcity was veriﬁed using recombinant γ2-3B in western
blot (Supplement Fig. S4). Mouse heart contains 5–10 timesmore of the
γ2-3B protein than any other tissue we have sampled; no γ2-3B was
detected in skeletal muscle or in kidney, and it appears that the protein
is largely cardiac speciﬁc (Fig. 8A). In order to estimate the relative
abundance of the various γ2 variants in the heart and their subcellular
localization,western blotswere performed onmouse heart fractionated
using a differential detergent extraction method to generate nuclear,
membrane, cytoskeletal and soluble fractions. A pan-γ2 antibody,
raised against a peptide that overlaps the junction between the N-
terminal extension of γ2-long/γ2-3B and the N-terminus of γ2-short,
was used. The γ2 proteins were almost exclusively located in the cyto-
skeletal fraction (Supplement Fig. S5A) and within this fraction bands
corresponding to γ2-3B and γ2-short were the major γ2 proteins
(Fig. 8B). Three γ2 proteins were also detected with a γ2 C-terminal
antibody, kindly provided by D. Carling (Supplement Fig. S5B).4. Discussion
4.1. Cardiac-speciﬁc γ2 transcript variant
This study set out to gain insight into the expression of PRKAG2 in
the heart and howmutations in this apparently ubiquitously expressed
gene cause a cardiac-restricted disease. Neither of the two well charac-
terized transcripts, γ2-long and γ2-short, are cardiac-speciﬁc in human
[5] or in mouse (Fig. 1) and there is no embryonic preference for either
γ2 transcript as both are expressed in early embryos (Fig. 2). However,
there is an intermediate γ2 transcript variant that is also transcribed
from the PRKAG2 locus; it appears to be increasingly expressed in the
developing mouse heart and is largely cardiac-speciﬁc in adult. Since
transcription of this γ2 variant starts in exon 3b, an alternative exon
within intron 3, we have named this transcript γ2-3B.
Quantitative PCR conﬁrmed that γ2-3B is a major transcript in both
fetal and adult human heart. It accounts for 50–60% of total γ2 mRNA,
with γ2-short being the other signiﬁcant contributor. It is likely that
this newly identiﬁed γ2-3B transcript corresponds to the 3 kb γ2 mes-
sage earlier detected in a northern blot of human cardiac mRNA [5].A B 
Fig. 8. Expression of the γ2-3B protein in mouse tissues — Western blots. A: G2-3B antibod
fractions of the level in heart. Equal amount of protein (45 μg) was loaded in each lane. B: P
tibody (Atlas Antibodies) that recognizes all three γ2 proteins. Bands were quantiﬁed and4.2. The major AMPK γ2 protein is γ2-3B and γ2-short in heart
Consistent with the transcript data (Fig. 7B), the γ2-3B and γ2-
short variants comprise the large majority of γ2 protein in mouse
heart (Fig. 8B). This ﬁnding contradicts earlier western blot data
which indicated that γ2-long is almost the only form of γ2 protein
in the heart [2,17]. However, our protein data are not only consistent
with our transcript results but are also supported by the northern blot
data of Lang et al. [5] which clearly shows the γ2-long to be a minor-
ity transcript in the heart.
While γ2-short is more uniformly expressed in mouse tissues, γ2-
3B is largely cardiac-speciﬁc (Fig. 8A), suggesting that alterations to
the function of γ2-3B may be responsible for the predominant cardiac
phenotype produced by mutations in the PRKAG2 gene. The PRKAG3
mutation which causes glycogen accumulation in skeletal muscle in
both pig and human [20,21], does so by affecting the γ subunit speciﬁc
to skeletalmuscle; we suggest that, in an analogousway, PRKAG2muta-
tions may act via γ2-3B, a cardiac speciﬁc γ subunit.4.3. Embryonic expression pattern of γ1 and γ3
The investigation of the expression pattern of the other γ regula-
tory subunits yielded unexpected observations. Surprisingly, γ3 was
detected in early embryos by in situ hybridization and by immunohis-
tochemistry. In early mouse embryos (8–8.5 dpc) there was no expres-
sion of γ1, the major AMPK regulatory subunit in adults [2]. Both short
and long γ2 transcriptions were detected in distinct structures of the
developing neuromuscular system (e.g. somites, neural ectoderm).
The γ2 and γ3 subunits appear to act as the early “embryonic” AMPK
regulatory subunits, rather than γ1. We ﬁrst detected the γ1 protein
in 10.5 dpc embryos in which the staining was localized only to certain
neural structures. However, increased γ1 expression was observed
at later stages of embryogenesis in the developing mouse heart and
γ1 becomes the major AMPK regulatory subunit in adult [2]. The γ1
knockout mouse does not suffer embryonic lethality nor has any
marked cardiac phenotype in adult [22], and thismay reﬂect the limited
embryonic role of γ1.
The recent publication of Kim and co-workers analyzed develop-
mental and disease-related changes in AMPK subunit expression [19].
However, the analysis of γ2 expression focused on γ2-short, γ2-long
and γ2c and did not include γ2-3B. We have not detected substantial
γ2c expression in human or mouse heart, and in mouse γ2c was
mostly detected in brain (Supplement Fig. S2).y, speciﬁc to γ2-3B; the intensities of the protein bands were quantiﬁed and plotted as
roteins in the cytoskeletal fraction of mouse heart were probed with anti-PRKAG2 an-
expressed as % of total γ2 (n=3).
348 K. Pinter et al. / Journal of Molecular and Cellular Cardiology 53 (2012) 342–349The “γ2-long” primer pair used in the early stages of our work was
capable of amplifying a fragment from both γ2-3B and γ2-long tran-
scripts; as γ2-long is a small fraction of total γ2 in the heart (Fig. 8B),
the increase of “γ2-long” expression in the embryonic mouse heart
was likely due principally to the increasing expression of the γ2-3B
form. We tested the presence of γ2-3B transcript in the embryonic
developing mouse heart (Supplement Fig. S6) and found that tran-
scription of γ2-3B occurred from 13.5 dpc and increased during
development; moreover the pattern resembled the increase of
“γ2-long" observed earlier (Fig. 5).
The fetal-adult transition from γ3 (which is present in glycolytic,
white skeletal muscles in the adult [17]) and γ2-short to γ1 and
γ2-3B might be attributed to a metabolic switch at birth when oxida-
tive metabolism replaces the mainly glucose and lactate utilization
via glycolysis [23,24].4.4. Implications of the speciﬁc staining patterns in the heart
The similar staining of cardiac structures during development
with γ3 and γ2-long antibodies (e.g. the atrio-ventricular junction)
suggests that AMPK trimers containing these γ subunits might have
similar functions. Lesions in the atrio-ventricular junction have been
previously shown in patients with γ2 mutations and it was also
found in the γ2 Asn488Ile transgenic mouse [25,26]. Therefore
these lesions might allow for accessory pathways and later conduc-
tion block. However, it has to be noted that no conduction defects
have been observed in either pigs with γ3 mutations [20,27] or in
the transgenic mice that mimic the porcine phenotype [28,29]
suggesting that γ2 may either have a different or more signiﬁcant
role during development in this region.4.5. Implications of the cardiac speciﬁcity of AMPK γ2-3B
Since the heart has relatively more AMPK γ2 than other tissues
with the majority being γ2-3B, it is possible that the mainly cardiac
phenotype caused by γ2 mutations is mediated via the γ2-3B variant.
In addition, AMPK complexes containing the different γ2 variants
may have different functions and localizations, interacting with dif-
ferent proteins and linking the speciﬁc AMPK trimers to different
signalling pathways. It has been reported that γ1 directs AMPK to
the Z-line in differentiated myoﬁbres [30] and α2/β2/γ3 complexes
are preferentially activated upon certain exercise regime [31]. By
extracting proteins from different cellular fractions we found all γ2
proteins almost exclusively in the cytoskeletal fraction of mouse
cardiomyocytes (Supplement Fig. S6) suggesting that γ2-AMPK is
mainly associated with sarcomeric structures. Using a yeast two-
hybrid screen of a human heart cDNA library, we have identiﬁed car-
diac troponin I as an interactor with amino acids 1–273 of γ2-long, a
region that includes overlap with γ2-3B [32]. However, further inves-
tigation is required to detect the possible differential compartmental-
ization of the γ2-AMPK complexes and to establish whether AMPK
complexes with different γ2 variants are linked to different cellular
processes.5. Conclusions
We have demonstrated that a third AMPK γ2 variant, γ2-3B, is in-
creasingly expressed in the developing heart. Since the expression is
largely cardiac-speciﬁc, PRKAG2 mutations most likely cause the
cardiac-restricted phenotype via changes in the function and/or local-
ization of γ2-3B-AMPK. The embryonic expression proﬁle of the other
AMPK regulatory subunits (γ1, γ3) has also been investigated and
established that γ2 and γ3 are the early embryonic AMPK regulatory
subunits.Disclosures
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